The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 19, 2021
Filed:
Oct. 05, 2015
Vir Biotechnology, Inc., San Francisco, CA (US);
Triad National Security, Llc, Los Alamos, NM (US);
Oregon Health & Science University, Portland, OR (US);
Eric Bruening, Damascus, OR (US);
Klaus Frueh, Portland, OR (US);
Louis Picker, Portland, OR (US);
Bette T. M. Korber, Santa Fe, NM (US);
James Theiler, Santa Fe, NM (US);
Emily Marshall, Portland, OR (US);
Vir Biotechnology, Inc., San Francisco, CA (US);
Triad National Security, LLC, Los Alamos, NM (US);
Oregon Health & Science University, Portland, OR (US);
Abstract
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.